Apogee Therapeutics, Inc. (APGE) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-243.89M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.83× | Operating cash flow / net income. Period ending 2026-06-30. $-243.89M ÷ $-294.37M ≈ 0.83× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -243.89M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -294.37M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-243.89M | (m) | (m) | (m) | (m) | $-294.37M | (m) | (m) | (m) | 0.83× |
| 2026-03-31 | (m) | (m) | $-234.54M | (m) | (m) | (m) | (m) | $-274.62M | (m) | (m) | (m) | 0.85× |
| 2025-12-31 | $-232.60M | (m) | $-227.45M | $5.15M | (m) | (m) | (m) | $-255.84M | (m) | (m) | (m) | 0.89× |
| 2025-09-30 | $-237.56M | (m) | $-232.47M | $5.08M | (m) | (m) | (m) | $-253.67M | (m) | (m) | (m) | 0.92× |
| 2025-06-30 | $-226.58M | (m) | $-220.74M | $5.83M | (m) | (m) | (m) | $-237.67M | (m) | (m) | (m) | 0.93× |
| 2025-03-31 | $-193.13M | (m) | $-188.01M | $5.12M | (m) | (m) | (m) | $-205.39M | (m) | (m) | (m) | 0.92× |
| 2024-12-31 | $-172.33M | (m) | $-171.17M | $1.15M | (m) | (m) | (m) | $-182.15M | (m) | (m) | (m) | 0.94× |
| 2024-09-30 | (m) | (m) | $-133.21M | (m) | (m) | (m) | (m) | $-146.66M | (m) | (m) | (m) | 0.91× |
| 2024-06-30 | (m) | (m) | $-110.57M | (m) | (m) | (m) | (m) | $-118.48M | (m) | (m) | (m) | 0.93× |
| 2024-03-31 | (m) | (m) | $-95.84M | (m) | (m) | (m) | (m) | $-103.55M | (m) | (m) | (m) | 0.93× |
| 2023-12-31 | $-74.93M | (m) | $-74.76M | $167.00K | (m) | (m) | (m) | $-83.98M | (m) | (m) | (m) | 0.89× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.